Clinical trial
BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in…
NCT02694523 · AbbVie, Industry · Completed
Key facts
| NCT number | NCT02694523 |
|---|---|
| Title | BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis |
| Official title | BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent) |
| Lead sponsor | AbbVie, Industry |
| Collaborators | Boehringer Ingelheim Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Biological, Drug |
| Interventions | risankizumab, adalimumab, placebo for risankizumab, placebo for adalimumab |
| Enrollment | 684 |
| Start date | Mar 1, 2016 |
| Primary completion | Aug 1, 2017 |
| Completion | Aug 1, 2017 |
| First posted | Feb 29, 2016 |
| Last update posted | Jul 30, 2021 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: